Sulfur Hexafluoride
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Sulfur Hexafluoride
- Sulfur Hexafluoride: From Ultrasound Contrast Imaging to Benign Prostatic Hyperplasia
Sulfur Hexafluoride: From Ultrasound Contrast Imaging to Benign Prostatic Hyperplasia
One-Sentence Summary
Sulfur hexafluoride is an inert gas formulated as microbubbles (SonoVue) and used as an ultrasound contrast agent. The TxGNN model predicts it may be effective for benign prostatic hyperplasia, but there are 0 clinical trials and 0 publications supporting this prediction. The score appears to be a model artifact rather than a true therapeutic signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore licence record (the compiled data lists the product as an ultrasound contrast agent, microbubble dispersion for injection) |
| Predicted New Indication | Benign prostatic hyperplasia |
| TxGNN Prediction Score | 90.75% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, sulfur hexafluoride is a physiologically inert gas that is stabilised as microbubbles for contrast-enhanced ultrasound. It works by reflecting ultrasound waves, not by acting on a biological target.
No plausible mechanistic link to benign prostatic hyperplasia was identified. The agent has no known pharmacological action on prostate tissue. The high score of 0.91 is a model output only, and the drug's rank (34,010) is also far down the overall list. The same pattern appears in the other top predictions (vaginitis, vulvitis, vulvovaginitis, bacterial vaginosis, iritis, folliculitis), which most likely reflect knowledge-graph neighbourhood effects rather than real therapeutic potential.
The only prediction with any related literature is peripheral arterial disease (rank 5, L4). That literature describes sulfur hexafluoride microbubbles as a diagnostic tool for measuring muscle microperfusion, not as a treatment, so it is not a therapeutic repurposing.
Clinical Trial Evidence
Currently no related clinical trials registered for benign prostatic hyperplasia.
Literature Evidence
Currently no related literature available for benign prostatic hyperplasia.
For reference, literature exists for the rank 5 prediction (peripheral arterial disease), all diagnostic or preclinical:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 21487300 | 2011 | Clinical diagnostic study | Investigative Radiology | Feasibility of dynamic contrast-enhanced ultrasound to detect changes in muscle microcirculation and perfusion reserve in PAD patients versus healthy volunteers |
| 24418637 | 2015 | Preclinical (porcine) | Journal of Vascular Surgery | Steady-state contrast-enhanced ultrasound to assess muscle microperfusion in a model of arterial stenosis |
| 26190189 | 2015 | Preclinical (animal) | J Vasc Interv Radiol | Effect of catheter-based sympathetic denervation on muscle microperfusion, measured by contrast ultrasound |
| 1288090 | 1992 | Preclinical (dog) | Adv Exp Med Biol | Hypoxic pulmonary vasoconstriction in acute lung injury; tangential to this drug |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN12349P | SonoVue Powder for Dispersion for Injection 8 microlitres/ml | Injection, powder, for solution | Not stated in the record |
Safety Considerations
Please refer to the package insert for safety information. No drug interactions were found in the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on model output alone (L5), with no clinical trials, no literature, and no plausible mechanism for an inert imaging gas acting on prostate tissue. The other top predictions show the same weakness, and the only literature found concerns diagnostic imaging rather than treatment.
To proceed, the following is needed:
- Singapore package insert (warnings, contraindications, approved indication), which is currently missing and blocks safety screening
- Mechanism of action data from DrugBank
- A credible pharmacological hypothesis linking the agent to prostate disease before any further evaluation
- If any direction is pursued, consider the diagnostic imaging use (for example, perfusion assessment in peripheral arterial disease) as a research question rather than a therapeutic repurposing
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.